Table 1.
Ongoing clinical trials of TCR engineered (TCRe) T cells in hepatocellular carcinoma.
| NCCT | Phase | Type | Product | Target | Organ | Pop | Sponsor | Primary Endpoint | Start Date |
|---|---|---|---|---|---|---|---|---|---|
| NCT02719782 | I | TCRe | HBV-TCR T cell | HBV Ag | HCC HBV+ | 10 | Lion Company | Safety | 06/2015 |
| NCT03132792 | I | TCRe | AFPᶜ332 T cells | AFP | basket | 45 | Adaptimmune | Safety | 05/2017 |
| NCT03441100 | I | TCRe | IMA202-101 | MAGEA1 | basket | 15 | Immatics | Safety | 05/2019 |
| NCT03899415 | I | TCRe | HBV-TCR T cell | HBV Ag | HCC HBV+ | 10 | Beijing Hospit. | Safety | 06/2019 |
| NCT04368182 | I | TCRe | Autologous C-TCR055 | AFP | HCC | 5 | Zhejiang Univ. | Safety | 06/2020 |
Abbreviations: Ag: antigen; AFP: alpha-fetoprotein; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; MAGE: melanoma antigen gene, TCRe: TCR engineered T cells.